Scarica l'app Stockscreener
0.2679
10.70%
-0.0321
Dopo l'orario di chiusura:
.28
0.0121
+4.52%
Precedente Chiudi:
$0.30
Aprire:
$0.259
Volume 24 ore:
773.75K
Relative Volume:
0.10
Capitalizzazione di mercato:
$942.15K
Reddito:
$54,200
Utile/perdita netta:
$-22.30M
Rapporto P/E:
-0.0227
EPS:
-11.793
Flusso di cassa netto:
$-12.98M
1 W Prestazione:
-28.20%
1M Prestazione:
-51.29%
6M Prestazione:
-92.82%
1 anno Prestazione:
-97.62%
Intervallo 1D:
$0.25
$0.2927
Intervallo di 1 settimana:
$0.25
$0.43
Portata 52W:
$0.25
$17.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Nome
Hcw Biologics Inc
Settore
Industria
Telefono
954-842-2024
Indirizzo
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.2679 | 942.15K | 54,200 | -22.30M | -12.98M | -11.79 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Hcw Biologics Inc Borsa (HCWB) Ultime notizie
Growth Recap: Will HCW Biologics Inc outperform tech stocksEarnings Risk Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Q4 revenue drops sharply on license suspension - TradingView
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
HCW Biologics (NASDAQ: HCWB) outlines immunotherapy pipeline, deals and IP - Stock Titan
HCW Biologics (NASDAQ: HCWB) 2025 loss, going concern and Nasdaq risk - Stock Titan
Hair-loss trial starts as HCW Biologics warns on funding runway - Stock Titan
HCW Biologics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Growth Value: Is HCW Biologics Inc gaining market shareDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HCWB Should I Buy - Intellectia AI
HCWB (HCW Biologics) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
HCWB Technical Analysis & Stock Price Forecast - Intellectia AI
Forecast Cut: Will HCW Biologics Inc benefit from green energy policiesWeekly Stock Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World
If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
HCW Biologics receives $7M upfront fee from China licensee - Investing.com
[8-K] HCW Biologics Inc. Reports Material Event - Stock Titan
HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative
Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network
Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat
HCW Biologics Inc. (HCWB) Stock: Science Advances Study Highlights Next-Gen CAR-T Manufacturing Strategy - parameter.io
HCW Biologics’ compound shows promise in CAR-T cell production By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To Keep An Eye OnMarch 16th - MarketBeat
Trading Volume Surges in Biotech, Tech, and Energy Stocks | Market RecapNews and Statistics - IndexBox
HCW Biologics (HCWB) spikes 71% as micro-cap volatility returns after Nasdaq compliance and recent financing - Quiver Quantitative
HCW Biologics announces positive research results for CAR-T cell therapy - TipRanks
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Asianet Newsable
HCW Biologics’ compound shows promise in CAR-T cell production - Investing.com
HCW Biologics reports positive CAR-T cell therapy research results By Investing.com - Investing.com Australia
HCW Biologics Announces Positive Research Results for CAR-T - GlobeNewswire
HCW Biologics (NASDAQ: HCWB) seeks approval for large warrant issuances and deep repricing - Stock Titan
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
Hedge Fund Moves: What is HCW Biologics Incs revenue forecastLayoff News & Low Risk Entry Point Tips - baoquankhu1.vn
AI Stocks: Will HCW Biologics Inc outperform tech stocksTrade Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
Buyout Rumor: Can HCW Biologics Inc stock double in the next yearWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
AI Stocks: Is HCW Biologics Inc forming a breakout patternWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
HCWB Earnings History & Surprises | EPS & Revenue Results | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - The Globe and Mail
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
Hcw Biologics Inc Azioni (HCWB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):